Trung Huynh Analyst PerformanceEquity Research - US Pharma and Biotech at UBS GroupTrung Huynh is a stock analyst at UBS Group in the healthcare sector, covering 11 publicly traded companies. Over the past year, Trung Huynh has issued 27 stock ratings, including buy, hold, and sell recommendations. While full access to Trung Huynh's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Trung Huynh's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access to unlock analyst rankings MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings48 Last 3 YearsBuy Recommendations59.09% 26 Buy RatingsCompanies Covered11 Unique Companies Ratings Distribution44RatingsDistribution of strong buy, buy, hold, and sell ratings by Trung Huynh.RatingPercentageCount Strong Buy0.0%0 ratings Buy59.1%26 ratings Hold36.4%16 ratings Sell4.5%2 ratingsOut of 44 total stock ratings issued by Trung Huynh at UBS Group, the majority (59.1%) have been Buy recommendations, followed by 36.4% Hold and 4.5% Sell.Best & Worst CallsBest Call000.0%INSMMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%JSPRFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNYSE54.5% of companies on NYSE6 companiesNASDAQ45.5% of companies on NASDAQ5 companiesTrung Huynh, an analyst at UBS Group, currently covers 11 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.Coverage FocusSector IconSectorPercentageHealthcare11 companies100.0%Trung Huynh of UBS Group specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY6 companies54.5%PHARMACEUTICALS5 companies45.5% Trung Huynh's Ratings History at UBS Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsJNJJohnson & Johnson10/14/2026Lower Price Target$249.93$280.00Outperform$0.0000.00% ROIABBVAbbVie10/13/2026Reiterated Rating$278.38$280.00Outperform$0.0000.00% ROIMRKMerck & Co., Inc.10/12/2026Lower Price Target$145.56$145.00Sector Perform$0.0000.00% ROILLYEli Lilly and Company10/12/2026Reiterated Rating$1,181.45$1,500.00Outperform$0.0000.00% ROIMRKMerck & Co., Inc.8/20/2026Downgrade$152.21$150.00Sector Perform$0.0000.00% ROIBMYBristol Myers Squibb7/31/2026Boost Price Target$65.27$64.00Sector Perform$0.0000.00% ROIABBVAbbVie7/10/2026Boost Price Target$249.75$280.00Outperform$0.0000.00% ROIMRKMerck & Co., Inc.7/8/2026Reiterated Rating$126.18$142.00Outperform$0.0000.00% ROILLYEli Lilly and Company7/8/2026Boost Price Target$1,219.54$1,500.00Outperform$0.0000.00% ROIPFEPfizer6/9/2026Upgrade$25.67$25.00Sector Perform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. PFEPfizer4/20/2026Reiterated Rating$27.57$25.00Underperform$0.0000.00% ROIMRKMerck & Co., Inc.3/30/2026Reiterated Rating$117.36$142.00Outperform$0.0000.00% ROIMRKMerck & Co., Inc.2/25/2026Initiated Coverage$124.11$142.00Outperform$0.0000.00% ROIABBVAbbVie2/24/2026Initiated Coverage$228.44$260.00Outperform$0.0000.00% ROILLYEli Lilly and Company2/24/2026Initiated Coverage$1,042.68$1,250.00Outperform$0.0000.00% ROIPFEPfizer2/24/2026Initiated Coverage$27.14$25.00Underperform$0.0000.00% ROIBMYBristol Myers Squibb2/24/2026Initiated Coverage$61.61$60.00Sector Perform$0.0000.00% ROIBMYBristol Myers Squibb2/24/2026Initiated Coverage$61.32$60.00Sector Perform$0.0000.00% ROILLYEli Lilly and Company2/24/2026Initiated Coverage$1,030.30$1,250.00Outperform$0.0000.00% ROIMRKMerck & Co., Inc.2/24/2026Upgrade$122.52Moderate Buy$0.0000.00% ROIMRKMerck & Co., Inc.1/7/2026Boost Price Target$108.72$130.00Buy$0.0000.00% ROIAMGNAmgen1/6/2026Initiated Coverage$330.17$380.00Buy$0.0000.00% ROIINSMInsmed1/6/2026Lower Price Target$175.20$215.00Buy$0.0000.00% ROILLYEli Lilly and Company12/18/2025Reiterated Rating$1,067.23Neutral$0.0000.00% ROILLYEli Lilly and Company11/7/2025Boost Price Target$911.58$1,080.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals11/7/2025Boost Price Target$646.93$660.00Neutral$0.0000.00% ROIINSMInsmed10/31/2025Boost Price Target$192.72$223.00Buy$0.0000.00% ROIINSMInsmed10/14/2025Boost Price Target$163.94$194.00Buy$00.0000.00% ROIJSPRJasper Therapeutics8/15/2025Lower Price Target$2.99$25.00Buy$0.0000.00% ROIINSMInsmed8/8/2025Boost Price Target$107.36$133.00Buy$000.0000.00% ROILLYEli Lilly and Company8/8/2025Lower Price Target$627.50$895.00Buy$0000.0000.00% ROIAMGNAmgen8/6/2025Lower Price Target$284.05$317.00Neutral$000.0000.00% ROIREGNRegeneron Pharmaceuticals8/1/2025Reiterated Rating$545.46Neutral$000.0000.00% ROIAMGNAmgen7/21/2025Boost Price Target$296.13$326.00Neutral$000.0000.00% ROIINSMInsmed5/9/2025Lower Price Target$65.08$109.00Buy$000.0000.00% ROIAMGNAmgen5/2/2025Reiterated Rating$277.09$315.00Neutral$000.0000.00% ROILLYEli Lilly and Company5/2/2025Lower Price Target$825.10$1,050.00Buy$000.0000.00% ROIPFEPfizer4/30/2025Boost Price Target$24.14$25.00Neutral$00.0000.00% ROIBMYBristol Myers Squibb4/11/2025Lower Price Target$49.80$54.00Neutral$00.0000.00% ROIPFEPfizer4/8/2025Lower Price Target$21.75$24.00Neutral$00.0000.00% ROIReady to give options a try? Your first trade (Ticker included) -INSIDE (Ad)Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.Send me my free guideINSMInsmed3/6/2025Boost Price Target$75.02$110.00Buy$000.0000.00% ROICLDXCelldex Therapeutics2/13/2025Initiated Coverage$22.26$44.00Buy$00.0000.00% ROIJSPRJasper Therapeutics2/13/2025Initiated Coverage$5.49$38.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals1/16/2025Downgrade$703.43$738.00Neutral$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupRoyal Bank Of CanadaThe Goldman Sachs GroupCantor FitzgeraldWall Street ZenBarclaysMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
